



## SEQUENCE LISTING

<110> LIPPARD, STEPHEN J.  
BARNES, CARMEN M.  
HASKEL, ARIEL  
BARNES, KATIE R.

<120> COORDINATION COMPLEXES HAVING TETHERED THERAPEUTIC  
AGENTS AND/OR TARGETING MOIETIES, AND METHODS OF MAKING  
AND USING THE SAME

<130> MTV-061.01

<140> 10/755,855  
<141> 2004-01-12

<150> 60/439,729  
<151> 2003-01-13

<150> 60/505,088  
<151> 2003-09-23

<160> 18

<170> PatentIn Ver. 3.3

<210> 1  
<211> 13  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
peptide

<400> 1  
Cys Asn Gly Arg Cys Val Ser Gly Cys Ala Gly Arg Cys  
1 5 10

<210> 2  
<211> 9  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
peptide

<400> 2  
Cys Asp Cys Arg Gly Asp Cys Phe Cys  
1 5

<210> 3  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
peptide

<400> 3  
Cys Asn Gly Arg Cys Gly Gly  
1 5

<210> 4  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
peptide

<400> 4  
Ser Met Ser Ile Ala Arg Leu  
1 5

<210> 5  
<211> 4  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
peptide

<400> 5  
Gly Phe Gly Val  
1

<210> 6  
<211> 4  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
peptide

<400> 6  
Arg Phe Gly Gly  
1

<210> 7  
<211> 4  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
peptide

<400> 7  
Phe Gly Gly Ser  
1

<210> 8  
<211> 5  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
peptide

<400> 8  
Phe Gly Gly Ser Val  
1 5

<210> 9  
<211> 5  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
peptide

<400> 9  
Phe Gly Gly Ser Trp  
1 5

<210> 10  
<211> 5  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
peptide

<400> 10  
Gly Glu Arg Ile Ser  
1 5

<210> 11  
<211> 5  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
peptide

<400> 11  
Gly Glu Arg Leu Ser  
1 5

<210> 12  
<211> 5  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
peptide

<400> 12  
Gly Glu Arg Ala Gly  
1 5

<210> 13  
<211> 5  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
peptide

<400> 13  
Pro Ser Gly Thr Ser  
1 5

<210> 14  
<211> 5  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
peptide

<400> 14  
Met Ser Gly Thr Gly  
1 5

<210> 15  
<211> 4  
<212> PRT  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<400> 15

Val Ser Gly Thr  
1

<210> 16

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<400> 16

Leu Ser Gly Thr  
1

<210> 17

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<400> 17

Ile Ser Gly Thr  
1

<210> 18

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<400> 18

Cys Gly Phe Glu Cys Val Arg Gln Cys Pro Glu Arg Cys  
1 5 10